PolyPid Appoints UCSF Brain Tumor Center Director Mitchel S. Berger, M.D., to Oncology Advisory Board
Dr. Berger Brings Extensive Expertise in Deep Brain Tumor Treatment
The Company Expects to Initiate a Phase 1/2 Clinical Trial of OncoPLEX for Brain Tumors by the end of 2022
“Glioblastoma Multiform (GBM) is an aggressive and devastating disease that is extremely challenging to treat and can result in mortality in just six months or less if untreated,” said
OncoPLEX utilizes PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology to provide controlled local exposure of chemotherapy directly to the tumor site, potentially reducing local tumor recurrence, including chemotherapeutic resistant tumors, and metastasis. In
“As a nationally recognized expert in treating brain and spinal cord tumors, as well as tumor-related epilepsy in adults and children, it is an honor to have
OncoPLEX is PolyPid’s lead intra-tumoral product candidate in Oncology. OncoPLEX utilizes the Company’s novel PLEX technology to provide controlled local exposure to docetaxel, one of the most widely used chemotherapy agents, directly at the tumor site for few weeks to potentially reduce local tumor reoccurrence, the potential spreading of cancer cells, and ultimately improve the overall survival rate of cancer patients. Local delivery of drugs directly into the tumor site, especially in difficult to access tumors such as in the brain, may significantly improve the clinical outcome. The OncoPLEX intra-tumoral cancer therapy program has been evaluated successfully in various animal tumor models, including colon carcinoma and glioblastoma.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the potential of PolyPid’s OncoPLEX to significantly advance treatment of GBM, and the Company’s expectation to initiate a Phase 1/2 clinical trial of OncoPLEX for brain tumors by the end of 2022. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the
References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release.
Dikla Czaczkes Akselbrad
EVP & CFO
Source: PolyPid Ltd.